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Abstract
Following long-term infection with virus derived from the pathogenic GL8 molecular clone of feline immunodeficiency virus
(FIV), a range of viral variants emerged with distinct modes of interaction with the viral receptors CD134 and CXCR4, and
sensitivities to neutralizing antibodies. In order to assess whether this viral diversity would be maintained following
subsequent transmission, a synthetic quasispecies was reconstituted comprising molecular clones bearing envs from six viral
variants and its replicative capacity compared in vivo with a clonal preparation of the parent virus. Infection with either
clonal (Group 1) or diverse (Group 2) challenge viruses, resulted in a reduction in CD4+ lymphocytes and an increase in
CD8+ lymphocytes. Proviral loads were similar in both study groups, peaking by 10 weeks post-infection, a higher plateau
(set-point) being achieved and maintained in study Group 1. Marked differences in the ability of individual viral variants to
replicate were noted in Group 2; those most similar to GL8 achieved higher viral loads while variants such as the chimaeras
bearing the B14 and B28 Envs grew less well. The defective replication of these variants was not due to suppression by the
humoral immune response as virus neutralising antibodies were not elicited within the study period. Similarly, although
potent cellular immune responses were detected against determinants in Env, no qualitative differences were revealed
between animals infected with either the clonal or the diverse inocula. However, in vitro studies indicated that the reduced
replicative capacity of variants B14 and B28 in vivo was associated with altered interactions between the viruses and the
viral receptor and co-receptor. The data suggest that viral variants with GL8-like characteristics have an early, replicative
advantage and should provide the focus for future vaccine development.
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Introduction
Feline immunodeficiency virus (FIV) targets CD4+ helper T
cells by an initial high affinity interaction between the viral
envelope glycoprotein and CD134 (OX40) [1,2] and a subsequent
interaction with the chemokine receptor CXCR4 [3,4]. As
expression of CD134 is restricted to activated CD4+ (not CD8+)
T cells, FIV infection of the domestic cat results in an immune
dysfunction characterised by a progressive depletion of helper T
cells. The resulting AIDS-like immunodeficiency manifests with
chronic gingivitis and stomatitis, anorexia, cachexia, neurological
signs and an increased incidence of malignancy.
There are distinct differences in pathogenicity amongst FIV
strains. Infection with a cell culture-adapted strain of virus results
in an inapparent infection with low viral loads and stable CD4+ T
cell numbers [5]. In contrast, infection with a primary isolate of
virus, serially passaged in vivo during the acute phase of infection,
results in the development of a disease state characterised by a
high viral load, precipitous decline in CD4+ T cell numbers,
lymphoid depletion and susceptibility to opportunistic infections
[6]. The pathogenicity of different strains of FIV may be
influenced by both host and viral factors, for example variants
bearing mutations in the FIV orfA gene are defective for growth in
primary T cells [7–9] while the viral Vif protein permits evasion of
the antiviral activities of host APOBEC proteins [10].
The surface glycoprotein Env is a primary determinant of cell
tropism; in early infection the virus targets CD4+ helper T cells and
macrophages primarily, while in later infection tropism extends to
CD8+ T cells and B cells [11,12] and it would appear that early and
late isolates of virus may differ in the way they interact with the
primary receptor CD134 and their propensity for CD134-indepen-
dent infection [13,14]. The virus-receptor interaction may evolve
under the selective pressure of the humoral immune response; for
example, hypervariation in the V5 loop of Env associated with
escape from neutralising antibody alters the Env-CD134 interac-
tion, increasing sensitivity to antagonism by anti-CD134 antibody
while reducing sensitivity to inhibition by soluble CD134 [15].
Accordingly, selective pressure from the humoral immune response
may alter the cell tropism and pathogenicity of the viral variants that
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evolve. Such ‘‘late’’ viral variants that emerge in FIV infected cats
under the selective pressure of the humoral immune response may
mirror the emergence of CXCR4-dependent (X4) variants of HIV
with disease progression [16]. X4 variants emerge in approximately
50% of HIV-infected individuals, however, progression to AIDS
may also occur in the absence of X4 variants suggesting that there is
not a causal link between the presence of X4 variants and the
development of AIDS. While the emergence of viral variants with
the phenotype of ‘‘late’’ variants of FIV has been observed in vivo
[15], it is not known whether these variants are less pathogenic, or
whether they are transmitted poorly to naı¨ve animals, analogous to
the selective filtering of X4 variants of HIV following transmission
(reviewed in [17]).
Identifying the strains of virus that are transmitted between cats
is critical to the selection of strains for future formulations of FIV
vaccines. While a commercial FIV vaccine has been developed
and has demonstrated a degree of efficacy [18–22], the vaccine
failed to protect cats from challenge with the prototypic United
Kingdom subtype A strain, GL8 [23–27]. If GL8 is representative
of field strains of FIV, then the incorporation of antigens from
GL8-like viruses into the next generation of FIV vaccines would
seem prudent.
In previous studies, we followed experimental infection of cats
with a molecular clone of GL8 for a period of six years [5,28]. At
the end of the study, we observed the establishment of pools, or
‘‘swarms’’ of viral variants, each with distinct receptor usages and
sensitivities to neutralising antibodies [15,29]. Included within
these viral quasispecies, were viruses that were near identical to the
parent GL8 strain of virus [29]. As FIV is thought to be
transmitted between cats by fighting and biting, the entire pool of
viral variants could, potentially, be transmitted between cats,
circumventing barriers to transmission such as mucosal surfaces
[17]. In this study we set out to investigate what would happen to a
diverse GL8-derived inoculum following experimental transmis-
sion. Would diversity be maintained or would selected viral
variants dominate? Here we demonstrate that following transmis-
sion of a pool of viral variants, GL8-like viruses dominate and
appear to have a replicative advantage.
Materials and Methods
Ethics statement
This study was approved by the University of Glasgow
Institutional Animal Care and Use Committee (OLAW Assurance
A5181-01) ‘‘The control of feline retroviral infection in domestic
cats’’ and was conducted under licence from the UK Government
Home Office under the Animals (Scientific Procedures) Act 1986.
The use of recombinant viruses was approved by the Health and
Safety Executive under The Genetically Modified Organisms
(Contained Use) Regulations 2000.
Cells and viruses
MYA-1 [30], MCC-CD134 [1] and CLL-CD134 [13] cells
were cultured in RPMI 1640 medium, while HEK-293T were
maintained in Dulbecco’s modification of Eagle’s medium
(DMEM). Media for HEK-293T, MCC-CD134 and CLL-
CD134 were supplemented with 400 mg/ml G418. All media
were supplemented with 10% foetal bovine serum (FBS), 2 mM
glutamine, 0.11 mg/ml sodium pyruvate 100 IU/ml penicillin,
100 mg/ml streptomycin (complete medium). The medium for
MYA-1 cells was supplemented with conditioned medium from a
murine cell line (L2.3) transfected with a human IL-2 expression
construct (M. Hattori, University of Tokyo, Japan) at a final
concentration equivalent to 100 U/ml of recombinant human
IL-2, and 50 mM 2-mercaptoethanol. All media and supplements
were obtained from Invitrogen Life Technologies, Paisley, UK.
Figure 1. Immunological alterations following FIV infection.
Cats in Group 1 were challenged with clonal GL8 (variant B32), cats in
group 2 were challenged with the reconstituted quasispecies challenge
(B14, B19, B28, B30, B31 and B32) and control cats remained
unchallenged. Percentages of lymphocytes expressing (A) CD4 and (B)
CD8 were measured by flow cytometry and are shown as group means
+/2 SE. (C) CD4:CD8 ratios were calculated from the percentage of CD4
and CD8 positive lymphocytes and are displayed as group means +/2
SE. p-values for statistically significant differences between infected and
control groups are shown (Student’s t-test).
doi:10.1371/journal.pone.0054871.g001
FIV Quasispecies
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Experimental design
Six years post-infection of cat A613 with a molecular clone of
the GL8 strain of FIV, a viral quasispecies had evolved
comprising diverse variants with distinct biological properties,
including resistance to virus neutralising antibody and discernible
differences in the nature of the virus-receptor interaction [5,29].
In this study, we compared transmission of a reconstituted
quasispecies with transmission of the cloned virus. In order to
prepare a defined ‘‘quasispecies’’, env genes from five distinct
variants (B14, B19, B28, B30, and B31 [15]) and a single variant
identical to the parent GL8 clone (B32) were amplified and sub-
cloned into the GL8(MYA) molecular clone. Our aim was to
reconstitute a quasispecies representative of that isolated from cat
613 at post-mortem and comprising variants with distinct
sensitivities to either neutralising antibody, soluble CD134
(sCD134) or anti-CD134 antibody (7D6), and which had shown
variations in the way they utilised CD134 as a receptor [13,14]
(summarised in Fig. S1 and shown in detail in Figure S2).
Challenge viruses were prepared by transfecting the six
variants into HEK-293T cells and recovering into primary IL2-
dependent CD4+ T cells (MYA-1 cells). MYA-1 cells express
CD4, CXCR4 and CD134 at similar levels to mitogen-
stimulated helper T cells and support the replication of all
strains of FIV tested to date without applying a selective pressure
to viruses cultured therein. Stocks of each virus were 0.45 mm-
filtered and frozen at 280uC. Viral titres were quantified by
serial dilution upon uninfected MYA-1 cells and calculated using
the Ka¨rber formula, monitoring the cells visually for cytopathi-
city and for the production of FIV p24 by enzyme-linked
immunosorbent assay (ELISA, PetCheck FIV antigen ELISA,
IDEXX Corp., Portland, Maine, USA). Reverse transcriptase
activity within each viral stock was estimated by non-isotopic RT
assay (Cavidi AB, Uppsala, Sweden).
Previous studies have demonstrated that four animals per group
would be sufficient to distinguish differences in the biological
phenotypes of the challenge viruses [5]. Accordingly, two groups
of four age-matched specific pathogen free animals were infected
with 10,000 TCID50 of either the parent molecular clone of GL8-
B32 (animals 821, 822, 823 and 824) or a pool containing equal
TCID50 of six variants bearing the env genes of B14, B19, B28,
B30, B31 and B32 to a final combined challenge dose of 10,000
TCID50 (animals 825, 826, 827 and 828). Thus, Group 1 received
10,000 TCID50 of clonal virus, while Group 2 received 10,000
TCID50 of the quasispecies (Figure S3). Animals were infected
intra-peritoneally and blood samples collected at three-weekly
intervals. EDTA-anti-coagulated blood samples were processed for
flow cytometry while plasma was stored for immunoblotting.
White blood cells were prepared using whole blood lysis and
frozen immediately at 280uC for subsequent analysis of proviral
loads. At post-mortem, 21 weeks post-infection, lymphoid tissues
Figure 2. Proviral loads following FIV infection. Mean proviral loads (+/2SE) for groups 1 (clonal challenge) and 2 (quasispecies challenge)
were estimated by real-time PCR using primers derived from either (A) gag (all clones shared a common gagpol sequence) or (B) a conserved
sequence within the V5 region of env. (C) The mean proviral loads (+/2SE) for individual variants B14, B19, B28 and B30 in study group 2 were
estimated using real-time PCR targeting unique determinants within the V5 region of env. All estimates of proviral load were performed in triplicate.
(D) V5 env sequences amplified at 21 weeks post-infection from cats 825, 826, 827 and 828 infected with the reconstituted quasispecies. The region
spanning nucleotides 1640 to 1694 of the GL8 env open reading frame is shown, the predicted amino acid translation of this region from the parent
GL8 strain is shown above the parent GL8 sequence. The number of clones isolated with the corresponding V5 sequence is listed; no clones bore the
B14 sequence, consistent with the poor replication of B14 in vivo.
doi:10.1371/journal.pone.0054871.g002
FIV Quasispecies
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were collected and processed, the separated cells were then cryo-
preserved for subsequent ELISpot analyses.
Flow cytometry
Anti-feline CD4-FITC (vpg34), anti-feline CD8ab-PE (vpg9) and
anti-human CD14-FITC (TU¨K4) were obtained from AbD Serotec
Ltd., Oxford, U.K. EDTA anti-coagulated blood was processed for
flow cytometric analyses by whole blood lysis as described previously
[31]. Samples were analysed on a Beckman Coulter EPICS MCS-
XL flow cytometer, 10,000 events being collected for each sample in
LIST mode. Data were processed using EXPO 32 ADC Analysis
software (Advanced Cytometry Systems).
Immunoblotting
Pooled supernatants from FIV GL8-infected MYA-1 cells were
filtered at 0.45 mm and virus pelleted by ultracentrifugation at
28,000 rpm in an SW28 rotor on a Beckman L8-70 ultracen-
trifuge. The pelleted virus was resuspended in reducing Laemmli
sample buffer [32] and separated on 4–15% polyacrylamide gels.
Separated proteins were transferred to nitrocellulose by electro-
blotting (iBlotTM, InVitrogen Life Technologies, Paisley, UK)
and viral antigens were detected using either cat plasma samples
or control pooled polyclonal cat plasmas from either uninfected
or FIV GL8-infected cats. Bound antibodies were detected using
biotinylated goat anti-cat IgG (Vector Laboratories Ltd.,
Peterborough, UK), while bound conjugate was revealed using
the Vectastain ABC kit and 5-bromo-4-chloro-3-indolyl phos-
phate/nitroblue tetrazolium substrate (Vector Laboratories Ltd.).
Virus neutralising antibody (VNA) assays
FIV env gene expression constructs have been described
previously [1,13,14]. 5 mg of each VR1012-env construct and
7.5 mg of pNL4-3-Luc-E2R2 were co-transfected into HEK-293T
cells using SuperFect activated dendrimer (QIAgen, Crawley, UK)
as per manufacturer’s instructions. The nomenclature ‘‘HIV(FIV)’’
denotes an FIV Env protein on an HIV particle. Culture
supernatants were collected at 72 hours post-transfection, filtered
at 0.45 mm and frozen at –80uC until required. Target cell lines
were seeded at 56104 cells per well of a CulturPlateTM-96 assay
plate (Perkin Elmer, Life and Analytical Sciences, Beaconsfield,
UK) and used immediately. The cells were then infected with
50 ml of HIV (FIV) luciferase pseudotypes, cultured for 72 hours
and then luciferase activity quantified by the addition of 100 ml of
Steadylite HTSTM (Perkin Elmer) luciferase substrate prior to
measurement by single photon counting on a MicroBeta TriLux
luminometer (Perkin Elmer).
Plasmas were diluted 5-fold in MYA-1 culture medium and
then 25 ml of each dilution (in triplicate) was incubated with 25 ml
Figure 3. Serological response to FIV infection. Plasmas were collected from cats in group 1 (822, 823, 824) and group 2 (825, 826, 827 and 828)
at 0, 3, 6, 10, 12, 15, 18 and 21 weeks post-infection and were screened by immunoblotting against purified GL8 virus. Also shown are positive (+) and
negative (2) control plasma samples. Bands corresponding to matrix (MA) and capsid (CA) proteins, and the envelope glycoprotein (Env) are
indicated by arrows.
doi:10.1371/journal.pone.0054871.g003
FIV Quasispecies
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of HIV(FIV) luciferase pseudotype (containing ,50 pg of reverse
transcriptase (RT) activity), incubated for one hour at 37uC and
then added to 50 ml (56104 cells) of MYA-1 cells per well of a
CulturPlateTM-96 assay plate (Perkin Elmer). The cells were then
cultured for 72 hours and luciferase activity quantified by the
addition of 100 ml of Steadylite HTSTM (Perkin Elmer) luciferase
substrate and measurement on a MicroBeta TriLux luminometer.
Percent neutralisation was calculated by comparing the mean
luciferase counts at each plasma dilution with the mean luciferase
counts for the no plasma control.
Inhibition of viral entry
16105 MYA-1, CLL-CD134 or MCC-CD134 cells were
incubated with AMD3100 in complete medium in triplicate wells
of 96-well culture-treated luciferase assay plates (CulturPlateTM
96) for 30 minutes at 37uC. HIV(FIV) pseudotypes were then
added and the plate returned to the 37uC incubator. Cultures were
maintained for 72 hours post-infection at which point 100 ml of
Steadylite HTSTM (Perkin Elmer) luciferase substrate was added
and luminescence measured by single photon counting on a
MicroBeta luminometer (Perkin Elmer). Percent infection was
calculated by comparing the mean (n = 3) luciferase activity of
each antagonist concentration against the mean (n = 3) luciferase
activity of untreated cells (100% infection).
Quantification of proviral loads by real time PCR
Primers and probes were purchased from Eurofins-MWG.
DNA was prepared from peripheral blood mononuclear cells
(PBMC) and stored in Tris-EDTA buffer prior to analysis. For
total viral loads, a gag PCR was utilized [33] whereby 400 ng of
Figure 4. Absence of neutralising antibodies in early FIV infection – Group 1. Sequential plasmas from group 1 (822, 823 and 824) animals
collected at 0,3,6,10,12,15,18 and 21 weeks post-infection were diluted 1:100 and assayed for the ability to neutralise HIV(FIV) pseudotypes bearing
the B32 Env. Also shown are pooled uninfected (2ve) plasma and post-mortem plasma from A613 (+ve). Neutralisation data are shown in comparison
with total proviral loads for each cat as estimated using either gag or env–specific real-time PCR. All estimates of proviral load and luciferase activity
are displayed as mean (n = 3) +/2 SE.
doi:10.1371/journal.pone.0054871.g004
FIV Quasispecies
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each sample was added to Taqman mastermix (Applied Biosys-
tems) containing 20 pmol of forward and reverse primers
FIV1360F (59-GCA GAA GCA AGA TTT GCA CCA-39) and
FIV1437R (59-TAT GGC GGC CAA TTT TCC T-39) and
10pmol probe FIV1416P FAM-TGC CTC AAG ATA CCA
TGC TCT ACA CTG CA-TAMRA. Single viral variant analysis
Figure 5. Absence of neutralising antibodies in early FIV infection – Group 2. Sequential plasmas from group 2 (825, 826, 827 and 828)
animals collected at 0,3,6,10,12,15,18 and 21 weeks post-infection were diluted 1:100 and assayed for the ability to neutralise HIV(FIV) pseudotypes
bearing the B14, B19, B28, B30, B31 and B32 Envs. Also shown are pooled uninfected (2ve) plasma and post-mortem plasma from A613 (+ve).
Neutralisation data are shown in comparison with total proviral loads for each cat as estimated using either gag or env–specific real-time PCR, or the
variant (B14, B19, B28 and B30)-specific V5-targeted real-time PCR. All estimates of proviral load and luciferase activity are displayed as mean (n = 3) +/
2 SE.
doi:10.1371/journal.pone.0054871.g005
FIV Quasispecies
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used a common reverse primer V5R1 (59- GCT ACG GGG TTA
TAC CAA TTT C-39) and probe V5probe1 (59- FAM-ATA GTG
TTA AAA TGG CAT GTC CTA AAA ATC AAG GCA TCT-
TAMRA-39), in conjunction with a unique forward primer B14F
(59-GTA CAA ATA GTA GTA GTA CAA ACA GTA GT-39),
B19F (59-ATA TGA ATT GTA ATT GTA CAA ATA GCA
Figure 6. Cellular immune response in FIV infected cats. Cells from popliteal (PLN) or mesenteric (MLN) lymph nodes, peripheral blood (PBMC)
or spleen were screened for interferon-c production by ELISpot using AT2-inactivated virus as the source of viral antigen (each point represents the
mean +/2SE of triplicate wells).
doi:10.1371/journal.pone.0054871.g006
FIV Quasispecies
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GTA CA-39), B28F (59-CAA ATA GTA GTA GTA CAA ATC
GGC AAA-39) or B30F (59-GTA CAA ATA GTA GTA GTA
CAA ATA GTA CA-39). It was not possible to generate a unique
V5 forward primer/probe combination for either clone B31 or the
parent clone GL8 (B32) that could distinguish B31 or GL8 from
the quasispecies as the V5 sequences of the viral variants were
derived from GL8. A primer and probe set targeting V5 but which
detected all variants with equal efficiency consisted of the primers
G8V57829F (59-GCA TTT CAA TAT GAC AAA AGC T-39)
and V5R1 and probe 59-FAM-ATA GTG TTA AAA TGG CAT
GTC CTA AAA ATC AAG GCA TCT-TAMRA-39. Control
amplifications used primers and probes adapted from ref. [33] and
targeting 18 s rDNA; rDNA 343F (59-CCA TTC GAA CGT
CTG CCC TA-39), rDNA 409R (52TCA CCC GTG GTC ACC
ATG-39) and probe rDNA 370P (59-FAM-CGA TGG TAG TCG
CCG TGC CTA-TAMRA-39). All estimations of viral load were
adjusted to control for efficiency of 18 s rDNA amplification.
Prior to the analyses, the specificities and sensitivities of the
variant-specific real-time PCRs were confirmed by comparing the
ability of each primer and probe set to detect i) the homologous
molecular clone in a background of cellular DNA and ii) the
homologous molecular clone in a background of cellular DNA that
had been spiked with an excess of the remaining five molecular
clones. By comparing the performance of the assays under these
conditions we were able to conclude that the B28 primer and
probe set could detect 62 copies of B28 proviral DNA in the
presence of 100,000-fold excess of the other five proviruses, at
which time cross-talk between templates could be detected. The
B30 primer and probe could also detect 62 copies of B30 but only
remained specific in the presence of a 1000-fold excess of the other
variants. The B14 primer and probe detected 62 copies with a
reduced specificity of a 100-fold while the B19 primer and probe
set proved the weakest of the four, with a sensitivity of 618 copies
and a specificity of only 20-fold. While by no means optimal, the
four primer and probe sets displayed sufficient specificity and
sensitivity to facilitate a sound estimation of the composition of
viral variants in peripheral blood. However, in order to confirm
that the real-time PCR analyses were robust, we used limiting
dilution PCR to amplify the V5 region of the env gene from PBMC
DNA prepared from post-mortem blood samples from cats 825,
826, 827 and 828, the products were cloned and the nucleic acid
sequences of approximately 50 clones from each animal were
Figure 7. Epitope mapping of the cellular immune response in FIV infected. T cell epitopes were mapped using spleen cells from
822,823,824,825,826,827 and 828. Analyses used 17 pools of 10 x 15-mer peptides, each overlapping by 10 amino acids (pools P1-P17).
Representative ELISpots for spleen cells from animal 822 against peptide pools P6 to p10) are included. All animals were screened with 17 peptide
pools and where strong responses were confirmed (*), individual epitopes were then identified by splitting pools into their component peptides and
repeating the analyses.
doi:10.1371/journal.pone.0054871.g007
FIV Quasispecies
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determined by capillary sequencing on an ABI3730xl DNA
analyzer (Applied Biosystems) using BigDyeH Terminator v1.1
cycle sequencing chemistry (Applied Biosystems).
Quantification of cellular immunity by ELISpot
Lymph nodes were removed at post mortem and placed in ice-
cold culture medium. Tissues were disrupted using crossed scalpels
and cells separated by pipetting, washed by centrifugation and
then purified by centrifugation through Ficoll-PaqueTM (GE
Healthcare UL Ltd, Little Chalfont, UK) separation medium.
Lymphocytes were harvested from the interface, washed by
centrifugation and stored in the vapour phase of liquid nitrogen
in cryoprotectant consisting of culture medium supplemented with
20% FBS and 10% DMSO. Prior to ELISpot analysis, cryovials of
cells were thawed rapidly at 37uC and washed in prewarmed
culture medium. IFN-c producing cells were enumerated using
commercial IFN-c ELISpot kits (R&D Systems, Abingdon,
Oxford, UK) as per the manufacturer’s protocol. 56105 cells
Figure 8. (A) Location of T cell epitopes identified by ELISpot on schematic representations of FIV gp120 and gp41. Each circle
represents a single amino acid, regions constituting T cell epitopes are marked by a red line with responding cat number alongside and peptide
names in parenthesis. Predicted sites for N-linked glycosylation are in blue. (B) Amino acid sequences of T cell epitopes covered by the ELISpot
peptides and the animals that responded.
doi:10.1371/journal.pone.0054871.g008
Table 1. Sensitivity of viral variants to receptor antagonists.
Viral variant
Target
cell B14 B19 B28 B30 B31 B32
anti-
CD1341
MYA-1 0.11 0.34 0.16 0.26 .50 .50
sFc-
CD134
MYA-1 25 1.1 18 1.6 1.4 0.7
MCC-
CD134
40 1.8 20 1.5 1.6 1.3
AMD3100 MYA-1 0.0045 0.06 0.03 0.02 0.035 0.025
CLL-
CD134
0.14 0.4 1.0 0.5 0.5 0.5
Inhibitory concentration 50% (IC50) in mg/ml.
doi:10.1371/journal.pone.0054871.t001
FIV Quasispecies
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were added to each well and incubated with 0.1, 1.0 or 10 mg (total
protein concentration) of sucrose gradient-purified FIV GL8 that
had been treated overnight with AldrithiolTM-2 (AT-2, Sigma,
Poole, UK). Control wells were incubated with medium alone or
medium supplemented with 5 mg/ml Concanavalin A (Con A).
Spot-forming cells were enumerated on an AID ViruSpot Reader,
CADAMA Medical Ltd., UK. Subsequent analyses used pools of
overlapping peptides derived from the predicted sequence of GL8
Env (15-mers overlapping by 10 amino acids and spanning the
entire leader (L), surface (SU) and transmembrane (TM) domains)
and which had been dissolved initially in HPLC-grade DMSO
(Sigma-Aldrich, Poole, UK) and diluted in phosphate buffered
saline pH 7.4 prior to use. All peptides were from Alta Biosciences
(Birmingham, UK).
Results
Comparison of viral pathogenicity in vivo
The replication of cloned GL8 (Group 1) in vivo was compared
with the reconstituted quasispecies (Group 2). While, infection of
both groups led to a significant reduction in the CD4:CD8 ratio
compared with age-matched controls (Fig. 1), there was no
significant difference in CD4:CD8 ratios between the two groups
at each of the time points that were compared. The reduced
CD4:CD8 ratios derived primarily from a reduction in CD4+ T
lymphocytes coupled with a significant increase in CD8+ T
lymphocytes as described previously [31]. This expansion of CD8+
lymphocytes reached a maximum by 12 weeks post-infection and
was sustained in group 2 animals but was transient in group 1
animals, falling to the control level by 21 weeks post-infection. By
21 weeks post-infection, CD4+ lymphocytes were depleted in both
study groups, but most markedly in group 1. Thus while infection
with the clonal virus appeared to induce a transient increase in
CD8+ lymphocytes and significant reduction in CD4+ lympho-
cytes, infection with the mixture of viral variants induced a
sustained increase in CD8+ lymphocytes and a more modest
reduction in CD4+ lymphocytes.
Next, we compared the proviral loads in peripheral blood
mononuclear cells (PBMC) between the two groups. As both
groups of cats were infected with viruses derived from the GL8
molecular clone, primers and probes for real time PCR were
designed that targeted the common gag sequence shared by all
viruses. When the 21-week area under the curve was compared no
statistically significant differences were found between groups 1
and 2, both groups achieving peak proviral loads approaching 105
proviral copies/106 cells. However, in general, the group 1 cats
infected with the homogeneous GL8 preparation achieved higher
absolute viral loads than group 2 infected with the quasispecies
(Fig. 2A), detectable by three weeks post-infection and peaking by
10 weeks post-infection. The sole exception was three weeks post-
infection where the viral loads in group 2 were higher than those
in group 1. Overall, even though the inocula were adjusted to
ensure that the animals were challenged with matched TCID50s,
the Group 2 inoculum with increased env diversity appeared to
replicate more poorly in vivo.
To confirm the validity of these findings, DNA was extracted
from a fresh set of PBMC samples and the analyses repeated using
primers and probes derived from a conserved stretch of the env.
This completely independent analysis (Fig. 2B) recapitulated the
findings with the gag primers and probe, demonstrating higher
proviral loads in the group 1 cats with the single exception of week
3, at which time point the situation was reversed. In conjunction
with the more pronounced reduction in CD4+ T lymphocytes, the
higher viral loads detected in the group 1 animals is consistent with
a higher viral load being linked to a more profound depletion of
CD4+ lymphocytes.
Next, we asked whether the lower viral load in the group 2
animals resulted from a defective ability to replicate per se, or
whether individual variants within the group 2 mixture were
affected more markedly than others. Despite the high degree of
sequence similarity amongst the six molecular clones comprising
the quasispecies, there was sufficient variation in the V5 region to
permit an estimation of the proviral loads of four of the individual
clones by real-time PCR using selective probe and primer sets
(Fig. 2C). These primers and probes did not detect the GL8-like
clones B31 and B32 (as the variant V5s were derived largely from
sequence repetition, it was not possible to detect B31 and B32
specifically in the presence of a background of B14, B19, B28 and
B30). Statistically significant differences were found in the 21-week
area under the curve among the four clones we were able to
discriminate (ANOVA p,0.05). B19 achieved a viral load of,104
copies/106 cells by three weeks post infection and this level was
maintained throughout the course of the study. B30 also achieved
a load of 104 copies/106 cells although not until 10 weeks post-
infection, suggesting replication may have been slightly retarded.
The most significant differences were the lower loads achieved by
B28 and, more strikingly, B14; both clones achieved substantially
lower viral loads (,103 copies/106 cells for B14) in spite of
matched TCID50 of all six viruses having been included in the
inoculum. Real time analyses of the number of viral genomes
within each of the individual virus stocks used to prepare the
challenge inocula revealed that each of the individual viral stocks
contributed ,109 viral genomes (range 1.3 to 6.06109) to the final
challenge stock following adjustment for in vitro titre. Thus the
marked disparity in viral loads observed in vivo could not be
accounted for by disparities in the number of viral genomes in the
challenge stocks. Specifically, the B14 stock contributed 2.26109
genomes to the challenge stock while B32 contributed 1.36109
genomes. The data suggest that the challenge stock for the group 2
cats had broadly similar numbers of genomes from each individual
virus and that the lower loads for B14 detected in vivo reflected a
failure of this viral variant to thrive in vivo.
Given the sensitivity and specificity of the real-time analyses (see
Methods), we can conclude that estimates of B28 and B30 copy
number are likely to be accurate; the total viral load in the group 2
cats (Fig. 2B) did not exceed ,104 copies and thus there would
have been insufficient competing templates to interfere with the
quantification of these variants. However, given that lentiviruses
acquire mutations with successive cycles of replication and that
such mutations may impact upon the accuracy of the real-time
PCR analyses, we performed a second analysis in which the V5
region of env was amplified directly from blood samples collected at
post mortem from the four animals infected with the quasispecies
(825, 826, 827, 828). The V5 amplicons were then cloned and
their nucleic acid sequences determined (Fig. 2D). The majority of
the amplicons sequenced from each of the four animals had V5
sequences identical to that of variants B31 and B32 (87% of total,
with two additional closely related variants, GL8v1 and GL8v2,
identified in animal 827), suggesting that by 21 weeks post-
infection the GL8-like variants were dominant in peripheral blood.
Variants B19 and B30 were detected at a lower frequency (6.8%
and 3.9%). Real-time PCR analysis had suggested that variants
B14 and B28 were present at significantly lower levels than the
other viral variants and this was borne out by the sequencing
analysis in that we were unable to detect B14 by direct sequencing
while B28-like variants were detected on only three occasions. The
data are consistent with the selective replication of GL8-like
variants during the early phase of infection.
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Role of neutralising antibodies in suppressing viral
replication
Pressure from the humoral immune response in the form of
virus neutralising antibody selects for the emergence of viral
variants bearing mutations in V5 that facilitate escape from
neutralisation and which may alter the nature the virus-receptor
interaction [15]. It is possible therefore that the replication of the
B14 and B28 variants was suppressed by the humoral immune
response although given that replication of these variants was
lower as early as 3 weeks post-infection this would seem unlikely.
To determine whether antibody-mediated neutralisation played a
role in the reduced replicative capacity of B14 and B28, we first
established whether the cats had mounted an anti-Env antibody
response within the 21 week study period. Sequential samples of
plasma from the infected animals were used to probe immuno-
blots prepared from pelleted IL2-dependent T cell-grown FIV
GL8 (Fig. 3). Sero-reactivity against the viral capsid protein p24
(CA) could be detected as early as three weeks post-infection
followed by a response against the matrix protein p17 (MA) at
6 weeks post-infection. Consistent with previous findings, the
humoral response to Env developed more slowly and in most cats
was not detectable until 10 to 12 weeks post-infection. At the
time of post-mortem, 21 weeks post-infection, all animals had
mounted a serological response against viral proteins, including
antibodies against Env.
Having confirmed the presence of Env-specific antibodies we
next asked whether virus neutralising antibodies contributed to the
humoral response and whether the strength of the neutralising
antibody response correlated with changes in the viral loads of
individual animals. Firstly, we examined neutralisation of the
clonal virus (B32) by homologous antibody from the Group 1
animals. While the PM plasma from cat 613 (+ve control)
neutralised homologous virus effectively, reducing infectivity by
over 100-fold (Fig. 4), no virus neutralizing antibodies were
detected in the sequential plasmas from animals 822, 823 and 824
(infected with the clonal inoculum), even though there was clear
evidence of a downward trend in viral load in cats 823 and 824
between 12 and 21 weeks post-infection. While all neutralisation
assays were performed with a level of input virus that displayed
marked neutralisation by plasma from cat 613, we considered the
possibility that very weak neutralising antibodies may be present in
the sequential plasmas and that these were masked by the level of
input virus. Accordingly, the neutralisation assays were repeated
with 10-fold and 100-fold reductions in the level of input viral
pseudotype, however, no neutralising activity was revealed in the
plasma samples irrespective of the level of input virus (not shown),
confirming that neutralising antibodies were not present in the
sequential samples.
We next investigated the neutralisation of the individual viral
variants in the group 2 cats (Fig. 5). As each animal had been
infected with a pool of six viral variants, sequential plasma samples
from each of the four animals were screened for neutralising
activity against HIV(FIV) pseudotypes bearing Envs from each of
the viral variants. Again, no neutralising activity could be detected
in any of the plasmas, while the positive control plasma from cat
613 neutralised the GL8-like variants B31 and B32 effectively.
Variants B14 and B28, which grew poorly in vivo, resisted
neutralisation by the sequential plasmas from all four animals.
Again, reducing the level of input virus in the assay did not reveal
the presence of weak neutralising antibody activity. As no
correlation was noted between proviral load and neutralising
antibody activity, the data do not support the involvement of
neutralising antibody in restricting the early growth of variants
such as B14 and B28.
Cellular response to viral infection
The cellular response to HIV infection develops during the
acute phase of viral replication and is thought to contribute
significantly to the reduction in viral load [34,35]. Moreover,
HIV-1 specific CD8+ T cells have been detected prior to the
detection of a humoral response [34–37]. The acute phase of
FIV infection is accompanied by the rapid expansion of a CD8+
lymphocyte population that is thought to represent an activated
T cell population responding to virus replication [31,38,39]. Both
Group 1 and Group 2 cats displayed such an expanded
population (Fig. 1) indicating that a cellular immune response
may have been induced in response to viral replication. Although
our understanding of cellular immunity in the cat is limited,
reagents have now been developed with which interferon-c
(IFNc) ELISpot assays may be performed [40,41]. We therefore
examined lymphoid tissues (popliteal and mesenteric lymph
nodes, and spleen) and peripheral blood mononuclear cells
collected at post mortem for evidence of a cellular immune
response using AldrithiolTM-2 (AT2)-inactivated whole GL8 virus
as the source of viral antigen. Responses varied between cats and
between tissues (Fig. 6). Amongst the cats infected with the clonal
virus preparation (group 1), a strong response was detected in the
PBMC of cat 822, while responses were not detected in either
popliteal or mesenteric lymph node samples and a weak response
was observed in spleen. In contrast, responses were detected in
the spleen, blood and popliteal lymph nodes of cats 823 and 824.
IFN-c-producing cells were detected in the spleens and
PBMCs of animals 825, 826, 827 and 828 challenged with the
quasispecies (group 2), but were less evident in the mesenteric
and popliteal lymph nodes, with the notable exception of 826 in
which marked virus-specific responses were evident in not only
spleen, but also both PBMC and mesenteric lymph node. It is
notable that 826 displayed very low viral loads for individual
variants B14 and B28 perhaps suggesting an involvement of the
cellular immune response in suppressing viral replication in this
animal.
Given the robust cellular responses detected in spleen cells from
the infected cats, we attempted to map the determinants in Env
recognised by the responding cells. As all animals were infected
with viruses that were identical in all genes except env, we reasoned
that any specificity in the cellular response for individual viral
variants would have to target Env. Accordingly, spleen cells from
animals in groups 1 and 2 (Fig. 7) were screened against 17 pools
of 10 overlapping 15-mer peptides representing the entire protein
encoded by the env gene. Positive pools were identified and the
analyses repeated using each of the individual peptides comprising
the positive pool. Cellular responses to the pooled peptides were
generally stronger than to inactivated virus as would be expected
due to enrichment of individual peptides. Using this strategy we
established that among the group 1 animals, pools P8 and P9 were
recognised by 822, pools P12 and P15 by 823 while pool P14 alone
elicited a response from 824 (Fig. 7). In contrast, among the group
2 animals, P9 stimulated a response from 825, three pools P2, P10
and P14 were recognised by 826, pools P8 and P9 were targeted
by 827, while 828 responded to a single pool, P15 (Fig. 7). The
data are consistent with the early cellular response targeting a
limited number of epitopes in Env.
Resolution of the pools revealed either individual peptides or
groups of peptides were responsible for driving the production of
IFN-c; for example, the response of 823 (group 1) to pool P12
could be mapped to peptide J3 while the epitope(s) in pool P9
recognised by 822 (group 1) and 827 (group 2) spanned peptides
H2 to H5. Superimposing the amino acid sequences of the
peptides recognised upon a schematic representation of FIV gp120
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and gp41 [32] (Fig. 8) revealed gp120 epitopes at the leader-
surface glycoprotein (L-SU) junction (B4-5), in the V3 loop (G2-5),
between V3 and V4 (H2-5) and C-terminal to V5 (J5) while gp41
epitopes mapped to the a-helical region of the extracellular
domain (K11) and a large epitope spanning the principle
immunodominant domain (PID) [33] and V7 (L9-10) recognised
by both 823 (group 1) and 828 (group 2). Three of the Env
epitopes were recognised by cells from two animals while a single
epitope elicited responses from the cells of three animals,
suggesting that these epitopes may be immunodominant. Howev-
er, we could find no correlation between the location of T cell
epitopes and the amino acid substitutions unique to each variant.
Additional ELISpot analyses performed using V5 peptides
representative of each of the six viral variants revealed no
evidence to suggest that the highly variable V5 loop encompassed
a T cell epitope (not shown). The data suggest that while robust T
cell responses are induced during the early phase of FIV GL8
infection and that they may contribute to the control of viral
replication, they are unlikely to account for the selective failure of
viral variants such as B14 and B28 to propagate following
experimental transmission.
Sensitivity of the viral variants to receptor antagonists
Of the six variants constituting the quasispecies, B14 achieved
the lowest viral load in vivo. As a reduced viral load was evident as
early as 3 weeks post-infection, it is unlikely that an adaptive
immune response was responsible for the poor replication of B14,
more likely would be either an increased sensitivity to an innate
control mechanism or a reduction in the efficiency of the process
of viral entry and spread. Previously, we observed that variants
B14 and B28 displayed an increased resistance to inhibition by
soluble CD134 coupled with an enhanced sensitivity to inhibition
by anti-CD134 antibody ([15]), indicative of alterations in the
virus-receptor interaction. For B14, modulation of the virus-
CD134 interaction was localised to the acquisition of mutations in
the V5 loop, apparently driven by escape from virus neutralising
antibodies [15]. Thus the two viral variants that achieved the
lowest viral loads in vivo also displayed an altered interaction with
the primary receptor CD134. We therefore extended these studies
to the interaction between the virus and its co-receptor CXCR4.
HIV(FIV) pseudotypes bearing Envs from GL8 or the five variants
were used to infect either MYA-1 cells (low CXCR4) or CLL-
CD134 (high CXCR4) in the presence of increasing concentra-
tions of the CXCR4 antagonist AMD3100 and the 50% inhibitory
concentration (IC50) estimated (Table 1). Infection with all six
variants was inhibited by AMD3100, consistent with obligate
usage of CXCR4 for entry by FIV. Lower concentrations of
AMD3100 were required to inhibit infection of cells expressing
low levels of CXCR4 (MYA-1) than high levels of CXCR4 (CLL-
CD134). Only one viral variant (B14) showed an enhanced
sensitivity to antagonism by AMD3100, most markedly on MYA-1
cells where CXCR4 was limiting. Thus, in addition to a high
sensitivity to anti-CD134 antibody and a low sensitivity to soluble
CD134, B14 was more sensitive to the CXCR4 antagonist. In the
absence of evidence for selective humoral or cellular control of the
early replication of this viral variant in the infected host, a
deficiency in the process of viral entry and spread may account for
the reduced ability to infect cells in vitro and the poor replication in
vivo.
Discussion
CD134 (OX40) is the primary receptor for FIV [1]; however,
viruses differ in the way they interact with CD134 [13,14]
(reviewed in [42]). These differences in the virus-receptor
interaction appear to be predictive of sensitivity to antagonism
by anti-CD134 antibody and soluble CD134, suggesting that
viruses may differ in the specificity and affinity with which they
interact with CD134. Previously, we proposed that viruses may
evolve in vivo from a complex, high affinity CD134 interaction (the
predominant phenotype in early, acute infection) to a more simple,
low affinity interaction (more prominent in late, chronic infection).
Consistent with this hypothesis, we observed the evolution of the
receptor usage of the ‘‘early’’ isolate GL8 in vivo and the emergence
of variants with the characteristics of ‘‘late’’ isolates [15]. If it is
indeed the case that GL8-like variants dominate in early infection,
then variants with the ‘‘late’’ phenotype must either not be
transmitted, or fail to thrive following transmission.
In this study we have addressed the latter scenario, by infecting
cats with a reconstituted quasispecies of ‘‘early’’ and ‘‘late’’
variants, we observed the preferential replication of GL8-like
‘‘early’’ variants. The basis for the failure of ‘‘late’’ variants to
thrive following transmission did not appear to stem from
immunological control; we could find no evidence for humoral
control of viral replication during the 21 week study period.
Further, while potent Env-specific cellular immune responses were
detected and their specificities mapped, there was no correlation
between the epitopes targeted and the replication of individual
viral variants. However, viruses that failed to thrive following
transmission, such as B14 and B28, were more sensitive to
antagonism by anti-CD134 antibody, resisted inhibition by soluble
CD134, and in the case of B14, displayed an enhanced sensitivity
to CXCR4 antagonist. Each of these observations is consistent
with alterations in the nature of the virus-receptor interaction in
variants such as B14 and B28, for example a reduced affinity of the
B14 and B28 Envs for the viral receptors. Our data suggest that
these alterations place the ‘‘late’’ variants at a replicative
disadvantage in naı¨ve cats.
Previous data have suggested that the neutralising response to
the GL8 strain of FIV develops very slowly [28]. In this study, we
could find no evidence to suggest that virus neutralising antibodies
played a significant role in the control of the GL8 strain of FIV
during the first 21 weeks of infection. Potent neutralising responses
have been observed in chronically infected cats (reviewed in [28]),
however this response may be focussed to a limited number of
determinants on Env such as the V4 and V5 loops and escape
from neutralisation has been observed [15,43–47]. Using HIV(-
FIV) pseudotypes bearing the Env proteins from each of the viral
variants within the inoculum we established that the strains that
replicated weakly in vivo were not targeted selectively by
neutralising antibodies during the 21 week study period.
Replication of GL8 induced significant cellular immune
responses in both study groups by 21 weeks post-infection, the
epitopes recognised varying between animals, an observation that
would be consistent with the out-bred study group possessing
distinct MHC and T cell repertoires. Mapping the cellular
responses proved informative: strong responses were detected
against epitopes in the V3–V4 region, perhaps indicating that at
least some of the pressure for antigenic variation in these regions
may come from the cellular immune response. Conversely, no
epitopes were detected in V5, the region that is most variable in
vivo, consistent with previous studies suggesting that this region
evolves to escape the humoral response [15,45]. Although we were
able to fine-map the determinants in Env targeted by the early
cellular response, no consistent pattern emerged to suggest that
cells infected with variants that replicated poorly were targeted
more efficiently by the cellular response. Given the potency of the
cellular immune responses detected, it is likely that there is a
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cellular element to controlling FIV GL8 replication during the
acute phase of infection but that additional factors act upon
variants such as B14 to stem viral spread.
Our data suggest that the variants that emerged late in the
infection of cat A613 have a reduced ability to infect diverse cells
types and that this may stem from alterations in the way they interact
with the viral receptors CXCR4 and CD134. The anti-CD134
antibody 7D6 competes very poorly with Env for binding to CD134,
suggesting that the inhibitory effect may be allosteric in nature [48].
GL8-like viruses are relatively resistant to 7D6, perhaps suggesting a
higher affinity interaction for CD134 than B14-like variants. Thus
GL8-like viruses may simply dominate in early infection as they
infect the primary target cells more efficiently. Once an infection has
been established, the immunological activation associated with
infection exemplified by lymphoid hyperplasia [26,27], enhanced
pro-inflammatory cytokine production [49] and polyclonal B cell
activation [50] may result in up-regulation of receptor expression
and thus create an environment that is conducive to the emergence
of viral variants displaying a reduced requirement for high affinity
receptor interactions.
The observation that GL8-like and B14-like viruses differ in the
way they interact with the viral receptors CD134 and CXCR4 is
consistent with findings that have revealed that HIV-1 clade B
envelopes from early infection tend to harbour amino acid
signatures that favour efficient Env expression in infected cells,
enhancing Env incorporation into nascent virions and replication
to higher titres [51,52]. These signature sequences are lost during
chronic infection under selective pressure from the adaptive
immune response [51,52]. Ex vivo assays of primary HIV-1 isolates
revealed that fitness mapped to the env gene and was controlled
predominantly during the early stages of viral replication [53,54].
For example, some type C HIV-1 envs displayed reduced fitness in
comparison with those of type B isolates and this was associated
with weak cell surface binding, inefficient entry, and an increased
sensitivity to CCR5 antagonists and fusion inhibitors [55]. By
analogy to these studies, we could hypothesize that FIV variants
such as B14 and B28 have an altered affinity for the viral receptor
or co-receptor that reduces fitness, translating to a lower
replicative capacity.
B14-like viruses may represent the end-product of selection by
the cellular and humoral immune responses upon FIV GL8;
viruses that emerge in chronic infection but which would be
supplanted rapidly by GL8-like viruses following transmission.
Whether B14-like viruses are able to disseminate or replicate in
distinct cellular compartments remains to be established, target
populations may include B cells or CD8+ T cells, however reliable
systems for the derivation and maintenance of feline CD8+ T cell
and B cell lines are not currently available.
The choice of immunogen is an important consideration for the
design of novel FIV vaccines. The data gathered from this study
would favour immunogens based on strains such as the parent
GL8 virus since it is this type of virus that dominates in early
infection and is responsible for the majority of the proviral burden
during the acute phase. In targeting such viruses selectively, novel
vaccines may not induce sterilising immunity, however they would
be more likely to prevent the establishment of a high viral burden
associated with rapid disease progression. Whether immunogens
can be designed that target such variants of FIV and HIV
effectively, inducing broad and long-lasting immunity remains one
of the greatest challenges in AIDS research.
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Env genes representative of five viral variants (B14, B19, B28, B30,
B31) and the parent virus (B32) were cloned into the GL8
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